RegulatoryCompany release

China approves HUTCHMED's Syk inhibitor SYVIK for chronic ITP and warm autoimmune haemolytic anaemia

HUTCHMED (China) Ltd (HCM) · Thu 19 Nov 2026

China's NMPA has cleared two applications for oral sovleplenib, covering adults with chronic primary immune thrombocytopenia and warm antibody autoimmune haemolytic anaemia.

HUTCHMED announced on 19 November 2026 that China's National Medical Products Administration (NMPA) has approved two new drug applications for SYVIK (sovleplenib), an oral spleen tyrosine kinase (Syk) inhibitor. The two approvals were granted at the same time.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): HUTCHMED (China) Ltd ↗

Article written by VigiEye from the official source (HUTCHMED (China) Ltd). Claims are the company's own. AI-assisted; check the source before acting.